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1. Introduction 
Diphosphoglycerate mutase (DPGM, bisphospho- 
glycerate synthase, EC 2.7 5.4) controls the concen- 
tration of 2,3-diphosphoglycerate (2,3-DPG) in 
erythrocytes [l-4]. The discovery that 2,3-DPG pro- 
foundly influences the affinity of haemoglob~ for 
oxygen [S ,6] has stimulated much interest in this 
system. It is now apparent that DPGM catalyses three 
reactions: the conversion of 1,3-diphosphoglycerate 
to 2,3-DPG; the dephosphorylation of 2,3-DPG; and 
the interconversion of 3- and 2-phosphoglycerates 
(2-41. 
These three reactions are also catalysed by the 
glycolytic enzyme, monophosphoglycerate mutase 
(MPGM, EC 2.7.5.3), although at different relative 
rates [2-4]. The two enzymes have other features in 
common including subunit size [2,7], tryptic peptide 
elution profiles f8], and a phosphorylated histidine 
intermediate [29]. A correlation of the amino acid 
sequence of yeast MPGM with its 2.8 A resolution 
electron density map shows two histidines (His 8 and 
His 179) at the active site [lo]. The sequence of a 
tryptic phosphohistid~e containing peptide from 
horse DPGM homologous with residues 8-l 5 of yeast 
MPGM has been determined [9]. 
We report here the isolation and ammo acid 
sequence determination of a 32 residue fragment 
from the N-terminus of human DPGM. A comparison 
with the yeast MPGM sequence shows them to be 
highly homologous, and implies a structurally very 
similar active site, and a common evolutionary origin. 
2. Materials and methods 
2 .I. truncation and characterization of ~~u~~ DEM 
DPGM was prepared from outdated human erythro- 
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cytes by the method in [2] except that the final puri- 
fication step involving af~nity chromatography on 
Blue Sepharose CLdB (Pharmacia) was altered. It was 
found that elution with 3-phosphoglycerate (Sigma, 
grade 1) instead of 2,3-DPG gave a better separation 
of DPGM from MPGM, which copurify until this step. 
The DPGM was characterized by enzymic assay, 
SDS-polyac~lamide gel electrophoresis, and ammo 
acid analysis, and was shown to be of adequate purity. 
2.2. Separation of CNBr fragments 
Purified DPGM (195 mg) was dialysed, freeze-dried 
and dissolved in 2 ml 70% (v/v) formic acid. A 50-fold 
molar excess of CNBr (Eastman) over methionine 
residues was added, and digestion was for 24 h at 
room temperature (15-2O’C). The CNBr fragments 
were separated on Sephadex G-75 eluted with 50% 
(v/v) formic acid. 
2.3. Subdigestion of CNBr jkagmertts 
Fragments (-400 nmol) dissolved in 1% (w/v) 
ammonium bicarbonate were digested by 200 yg 
trypsin or chymotrypsin (Worthington) for 18 h at 
37°C. The sub-peptides were purified by high-voltage 
paper electrophoresis. 
2.4. Analytical methods 
A Beckman 890C sequencer was used to deter- 
mine the sequence of fragment CN4. The phenylthio- 
hydanto~ (PTH) amino acids were identified by 
reversed-phase high-pressure liquid chromatography 
using Waters Associates equipment. PTH ammo acids 
were hydrolysed in evacuated tubes with 25 ~_ll 
hydriodic acid (BDH Chemicals) at 130°C for 20 h, 
and amino acid analysis done to confirm the PTH 
identi~cation. The sequence was completed and 
verified by isolating sub-peptides, and determining 
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their sequence by the manual dansyl-Edman proce- 
dure [ 1 l] if necessary. Peptides were hydrolysed in 
evacuated tubes with 0.5 ml 50% (v/v) Aristar HCI 
at 110°C for 20 h. Quantitative amino acid analysis 
was done using a Locarte amino acid analyser with a 
single column eluted by a 3.5 h sequence of 4 step- 
wise buffer changes. Tryptophan was detected after 
reactidn with Ehrlich reagent [ 121. 
3. Results and discussion 
3 .l . Isolation of CNBr fragments 
Human DPGM contains 4 methionine residues 
(table l), and the separation of the CNBr fragments 
is shown in fig.1. Fragments CN4 and CN5 elute 
together, and were separated by high-voltage paper 
electrophoresis. Their amino acid compositions, elec- 
trophoretic mobilities and N-termini are given in 
table 1. It is apparent from a correlation of the amino 
acid composition and electrophoretic mobility [ 131 
of CN5 (and also sub-peptide CN5TB2) that it has a 
blocked N-terminus, and therefore is derived from the 
N-terminus of DPGM. 
Fig.1. Gel filtration of CNBr fragments on Sephadex G-75. 
The CNBr digest was applied directly to a 2.5 X 1350 cm 
column that had been equilibrated with 50% (v/v) formic 
acid. The flow rate was 6 ml/h, and fractions of 2.5 ml were 
collected. Fractions containing CN4 and CN5 were pooled as 
indicated. 
3.2. Amino acid sequence of an active site fragment 
The amino acid sequences of fragments CN4 and 
CN5 are given in fig.2. The liquid-phase sequencer 
analysis was done on the pooled fractions indicated 
in fig.1, and therefore contained both fragments. The 
Table 1 
Peptide data 
Name CN4 CN5 TA TBl TBZ TB3 TCl TD4 TD5 ChB ChC ChE ChD3 ChD8 
"6.5 0 0 -0.34 0 0 0 +O.lO +0.55 +0.55 -0.41 -0.27 0 0 0 
ASX 3.9 
Thr 
Ser 2.0 
Glx 4.2 
PKO 
Gly 3.2 
Ala 1.1 
CYS 
va1 1.1 
11e 
LeU 2.0 
TY~ 
Phe 1.0 
His 0.8 
LYS 2.9 
Arg 1.9 
"se + 
T=P + 
Total 27 
0.9 
1.1 
1.0 
0.9 
+ 
5 
x-sex 
1.1 
0.9 
1.1 
1.0 
0.8 
+ 
6 
LeU 
1.0 
0.9 
+ 
3 
LeU 
1.0 
1.0 
2 
x-sex 
1.0 
0.9 
1.0 
3 
Glx 
1.8 
0.9 
2.1 
2.1 
1.0 
0.9 
0.8 
0.8 
0.6 
1.8 
+ 
7 
8 
Phe 
His 
1.0 
1 
LYS 
1.0 
1.0 
2 
LeU 
0.9 
0.9 
1.1 
1.2 
+ 
5 
1.8 
1.2 
1.8 
1.1 
1.0 
1.1 
0.9 
+ 
10 
va1 
1.0 
1.1 
1.0 
+ 
4 
LYS 
1.2 
1.0 
1.2 
1.0 
1.0 
0.9 - 
0.8 
2 5 
Ser Val 
Experimental details are given in the text. Composition values are molar ratios, and are uncorrected for 
destruction or partial hydrolysis. ( - ) means insignificant amount (d0.3). 
is expressed relative to the mobility of aspartic acid, 
Electrophoretic mobility 
using valine as a neutral marker 
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5 10 15 
C_CN5------l aCN4 ----W-W 
X-Ser-Lys-Leu-Ile-Met-Leu-Arg-His-Gly-Glu-Gly-Ala-Trp-Asn-Lys- 
..**>**-_)* 
I--ChEEl-TD5ik.-----TCl~~, 
+-TB2-l hTJl2 
20 25 30 
CN4 I 
Glu-Asn-Arg-Lys-Phe-Ser-Tyr-Val-Asp-Gln-Lys-Leu-Asn-Ser-Glu-Gly-Met 
l--TB3-lTD4I-----TC1------l+TA~ 
CChD3_(i---ChD8--+~Ch8--~ -+ 
aChC_ 
Fig.2. Ammo acid sequence of an active site fragment. Resi- 
dues identified from the sequencer (b) or by the manual 
dansyl-Edman procedure (-) are indicated. Degradation 
cycles for which no residue was identified are shown by 
(-). Peptide data are given in table I. The assignment of 
residue 13 as Trp is based on the compo~tions of peptides 
TCl , ChD3 and ChD8. Peptides TCI contained tryptophan 
as shown by positive reaction with Ehrlich reagent, whereas 
peptides ChD3 and ChD8 did not. 
presence of fragment CNS was not a problem since it 
has a blocked N-terminus and was not degraded, The 
sequence was completed and verified by purifying 
and partially. sequencing tryptic and chymotryptic 
peptides as shown in fig.1 and table 1. 
It is apparent from a comparison of the sequences 
in table 2 that fra~ellts CN4 and CN5 of DPGM 
correspond to the N-terminal, active-site region of 
yeast MPGM. The phosphohistidine peptide isolated 
from horse DPGM [9] is virtually identical to resi- 
dues 8-15 of the human enzyme with only a single 
amide difference. 
The sequence homology between the human 
DPGM and yeast MPGM would suggest hey have 
structurally similar active sites and would be consis- 
tent with their ability to catalyse the same reactions. 
The sequence similarity would also be consistent with 
the DPGM having evolved from the ubiquitous gly- 
colytic enzyme, MPGM. 
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